Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Microb Pathog ; 112: 1-4, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28923601

RESUMO

Studies show that highly diluted medications demonstrate benefits in treating infections, constituting an alternative for their treatment. The present study evaluated the effects of Lycopodium clavatum, dynamization 13c, in Wistar rats infected with T. cruzi. In this study 42 male rats were intraperitoneally inoculated with T. cruzi - Y strain and allocated into groups: IC (infected control group) and Ly (treated with L. clavatum 13c). The cytokines dosage (IFN-γ, IL-12, IL-10, IL-4), quantification and morphometry of myenteric neurons were evaluated. The treatment with L. clavatum modifies the immune response, with increase of IFN-γ on day 10 a.i. and IL-12 on day 24 a.i., decrease of IL-10 concentration on day 10 a.i. and subsequent increase of this cytokine and IL-4 on day 24 a.i., affording a bigger number of myenteric neurons compared to IC group. Thus, L. clavatum 13c promoted on rats infected with T. cruzi a beneficial immunomodulatory action reducing the pathogenic progression of digestive Chagas disease.


Assuntos
Doença de Chagas/imunologia , Imunomodulação , Lycopodium/química , Neurônios/imunologia , Extratos Vegetais/farmacologia , Trypanosoma cruzi/efeitos dos fármacos , Animais , Corpo Celular/efeitos dos fármacos , Corpo Celular/imunologia , Corpo Celular/parasitologia , Corpo Celular/patologia , Doença de Chagas/tratamento farmacológico , Colo/inervação , Colo/parasitologia , Colo/patologia , Citocinas/metabolismo , Digestão , Modelos Animais de Doenças , Homeopatia , Interferon gama/metabolismo , Interleucina-10/metabolismo , Interleucina-12/metabolismo , Interleucina-4/metabolismo , Masculino , Neurônios/efeitos dos fármacos , Neurônios/parasitologia , Neurônios/patologia , Ratos , Ratos Wistar , Trypanosoma cruzi/imunologia , Trypanosoma cruzi/patogenicidade
2.
Microb Pathog ; 110: 107-116, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28645772

RESUMO

Recent evidence includes apoptosis as a defense against Trypanosoma cruzi infection, which promotes an immune response in the host induced by T cells, type 1, 2 and 17. Currently, there is no medicine completely preventing the progression of this disease. We investigated the immunological and apoptotic effects, morbidity and survival of mice infected with T. cruzi and treated with dynamized homeopathic compounds 13c: Kalium causticum (GCaus), Conium maculatum, (GCon), Lycopodium clavatum (GLy) and 7% alcohol solution (control, vehicle compounds, GCI). There was significant difference in the increase of apoptosis in the treated groups, compared with GCI, which might indicate action of the compounds in these cells. Infected animals treated with Lycopodium clavatum presented better performance compared with other groups. GLy showed a higher amount of hepatocytes and splenocytes undergoing apoptosis, higher number of apoptotic bodies in the liver, predominance of Th1 response, increased TNF-α and decreased IL-6, higher survival, lower morbidity, higher water consumption, body temperature, tendency to higher feed intake and weight gain compared with GCI. Conium maculatum had worse results with increased Th2 response with increased IL-4, worsening of the infection with early mortality of the animals. Together, these data suggest that highly diluted medicines modulate the immune response and apoptosis, affecting the morbidity of animals infected with a highly virulent strain of T. cruzi, being able to minimize the course of infection, providing more alternative approaches in the treatment of Chagas disease.


Assuntos
Apoptose/efeitos dos fármacos , Doença de Chagas/tratamento farmacológico , Hepatócitos/efeitos dos fármacos , Lycopodium/química , Extratos Vegetais/uso terapêutico , Baço/efeitos dos fármacos , Trypanosoma cruzi/patogenicidade , Animais , Temperatura Corporal , Doença de Chagas/fisiopatologia , Conium/química , Citocinas/metabolismo , Fragmentação do DNA , Modelos Animais de Doenças , Ingestão de Líquidos , Hepatócitos/parasitologia , Hepatócitos/patologia , Interleucina-4/metabolismo , Interleucina-6/metabolismo , Masculino , Camundongos , Morbidade , Extratos Vegetais/administração & dosagem , Extratos Vegetais/farmacologia , Baço/parasitologia , Baço/patologia , Taxa de Sobrevida , Células Th1/imunologia , Células Th2/imunologia , Trypanosoma cruzi/imunologia , Fator de Necrose Tumoral alfa/metabolismo , Aumento de Peso
3.
Cytokine ; 88: 57-61, 2016 12.
Artigo em Inglês | MEDLINE | ID: mdl-27565835

RESUMO

We investigated the number of megakaryocytes, Kupffer cells and ratios of Th1/Th2 and Th1/Th17 cytokines in survival of mice infected with Y strain of Trypanosoma cruzi and treated with Lycopodium clavatum. In a blind, randomized and controlled assay, Swiss male mice, 8weeks-old, infected with 1400 trypomastigotes (Y strain) were divided into groups and treated with: GLy - Lycopodium clavatum dynamization13c and GCI - alcohol solution 7° GL (vehicle medicine). The treatment was offered two days before infection and on the 2nd, 4th and 6th days after infection, overnight (1mL/100mL) and ad libitum. Parameters assessed were: survival rate, number of megakaryocytes and Kupffer cells, cytokines dosage (TNF-α, IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-17), Th1/Th2 and Th1/Th17 ratios. The increase in megakaryocytes, Kupffer cells, predominance of Th1 response, with increased TNF-α, IL-10, TNF-α/IL-4, TNF-α/IL-17 and decreased IL-6 IL-6/IL-4, are related to increased survival in mice infected with T. cruzi and treated with Lycopodium clavatum 13c. This result demonstrates the possibility of an alternative approach for the treatment of Chagas disease with dynamized drugs.


Assuntos
Doença de Chagas/metabolismo , Citocinas/metabolismo , Células de Kupffer/metabolismo , Lycopodium , Megacariócitos/metabolismo , Células Th1/metabolismo , Trypanosoma cruzi/metabolismo , Animais , Doença de Chagas/tratamento farmacológico , Masculino , Camundongos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA